Repligen (RGEN) Projected to Post Earnings on Tuesday

Repligen (NASDAQ:RGEN) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, April 29th. Analysts expect Repligen to post earnings of $0.35 per share and revenue of $163.65 million for the quarter. Repligen has set its FY 2025 guidance at 1.670-1.760 EPS.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Stock Performance

RGEN stock opened at $145.23 on Friday. Repligen has a 1-year low of $102.97 and a 1-year high of $182.52. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.15 billion, a PE ratio of -284.76, a P/E/G ratio of 4.54 and a beta of 1.27. The business’s 50-day moving average price is $139.81 and its two-hundred day moving average price is $145.73.

Insider Activity

In other Repligen news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on RGEN shares. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Thursday, April 17th. JPMorgan Chase & Co. increased their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. HC Wainwright restated a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. Canaccord Genuity Group decreased their price objective on Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a report on Wednesday, April 16th. Finally, Royal Bank of Canada lifted their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $176.82.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.